Natera Inc(NTRA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.37 | Insider Own | 6.42% | Shs Outstand | 143.6M | Perf Week | 2.67% |
| Market Cap | 58.23B | Forward P/E | - | EPS next Y | 76.51% | Insider Trans | -6.72% | Shs Float | 134.9M | Perf Month | -1.18% |
| Enterprise Value | 57.37B | PEG | - | EPS next Q | -0.28 | Inst Own | 92.69% | Short Float | 4.71% | Perf Quarter | 56.55% |
| Income | -0.19B | P/S | 21.51 | EPS this Y | 4.32% | Inst Trans | 1.35% | Short Ratio | 4.31 | Perf Half Y | 98.26% |
| Sales | 2.71B | P/B | 31.85 | EPS next 5Y | - | ROA | -8.71% | Short Interest | 6.36M | Perf YTD | 76.33% |
| Book/sh | 12.68 | P/C | 53.35 | EPS past 3/5Y | 35.09% 11.7% | ROE | -12.54% | 52W High | -7.65% ($437.41) | Perf Year | 107.15% |
| Cash/sh | 7.57 | P/FCF | 691.53 | Sales past 3/5Y | 41.14% 42.61% | ROIC | -9.79% | 52W Low | 123.18% ($181.00) | Perf 3Y | 907.86% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 28.02% | Gross Margin | 64.74% | Volatility(W/M) | 4.36% 4.37% | Perf 5Y | 251.47% |
| Dividend TTM | - | EV/Sales | 21.19 | Sales Y/Y TTM | 37.82% | Oper. Margin | -10.56% | ATR (14) | 17.2 | Perf 10Y | 3943.54% |
| Dividend Ex-Date | - | Quick Ratio | 2.85 | EPS Q/Q | 36.85% | Profit Margin | -7.11% | RSI (14) | 57.23 | Recom | 1.44 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3 | Sales Q/Q | 37.71% | SMA20 | -0.04% ($404.11) | Beta | 1.55 | Target Price | $411.39 |
| Payout | - | Debt/Eq | 0.13 | Earnings | 2026/8/6 | SMA50 | 10.08% ($366.96) | Rel Volume | 0.75 | Prev Close | $401.37 |
| Employees | 6140 | LT Debt/Eq | 0.08 | EPS/Sales Surpr. | 4.84% 13.84% | SMA200 | 54.4% ($261.63) | Avg Volume(3M) | 1.47M | Price | $403.95 |
| IPO | 2015/7/2 | Option/Short | Yes/Yes | Trades | 18881 | Volume | 1,102,138 | Change | 0.64% |
🧬 A global genetic diagnostics company specializing in pregnancy, oncology, and transplant diagnostic solutions based on genetic analysis. Founded in 2003 and headquartered in California, USA, it has established itself as a key pillar of a leading diagnostic group in the fields of prenatal genetic testing, cancer residual disease testing, and post-transplant monitoring.
Over the past 1 year, on the higher side
8% below its 1-year high.
Traded less than usual. That is 75% of its average volume.
NTRA has a sound balance sheet but weak earning power
Of every $100 in sales, $10.56 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +4.3% this year.
Tap to view numbers
Relative to sales, it looks expensive
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $2,151. Peers typically go for $658.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +251.5%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 92.7%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #3 of 44 in the industry
Based on market cap of $58B.
FAQ
What kind of company is NTRA?
NTRA belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of NTRA?
The market cap of NTRA is approximately $58.2B, ranking 285 within its sector.
What is the 52-week high and low for NTRA?
NTRA has recorded a 52-week high of $437.41 and a low of $181.00.
